Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer - An Open Label, Non-comparative, Randomized, Multicenter Phase II Trial
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Cisplatin; Gemcitabine
- Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma
- Focus Therapeutic Use
- Acronyms NIFE
- 31 Aug 2018 Biomarkers information updated
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 22 Mar 2018 Status changed from not yet recruiting to recruiting.